On Mon, 5 Dec 2005 09:23, Dr John Van Dyck wrote: > Why not sent the data to HCN as requested (with proper disclaimers) and get > them to do a trial conversion to pinpoint any problems before even > attempting the conversion?
Personally, I'd rather go back to paper before I would ever consider letting a company known to have had commercial data exchange (even if "de-identified") with the pharmaceutical industry. HCN is a shareholder company, isn't it? They are not bound by ethical constraints - they are in fact obliged by LAW to do ANYTHING within legal limits to maximize shareholders value. I think most of us would agree that current legal limits don't intersect much with our professional ethics ... Meaning that even operating entirely within the law, they could act very much to the detriment of our patients and even *have to* if this is both profitable and legal. Horst _______________________________________________ Gpcg_talk mailing list [email protected] http://ozdocit.org/cgi-bin/mailman/listinfo/gpcg_talk
